Global NewsHigh Priority (8/10)

Big Pharma's Metabolic Health Race: Viking and Structure Become Top Acquisition Targets

As Big Pharma faces patent cliffs and pricing pressures, metabolic health companies like Viking Therapeutics and Structure Therapeutics have become the most sought-after acquisition targets, with Viking potentially valued at over $15 billion.

Key Points

  • Viking Therapeutics could be valued at over $15 billion in an acquisition
  • VK2735 shows best-in-class potential as dual GLP-1/GIP agonist
  • Acquisition premiums expected to exceed 100% of current market cap
  • Biosimilar competition will force acquirers to prove premium asset value by end of decade

Full Details

Big Pharma is pivoting toward metabolic health as the new backbone of modern medicine, driven by traditional blockbusters facing patent cliffs and IRA pricing pressures. Viking Therapeutics has emerged as the premier acquisition target due to VK2735, a dual GLP-1/GIP agonist demonstrating best-in-class potential in both injectable and oral formats. Analysts suggest any acquisition of Viking would require a premium exceeding 100% of its current market cap, potentially valuing the company north of $15 billion. The entry of biosimilars for early-generation GLP-1s toward the decade's end will force acquirers to prove their premium assets offer significantly better outcomes. Investors should watch for Phase 3 protocol finalization, FTC stance changes on biotech M&A, and tri-agonist data combining GLP-1, GIP, and Glucagon.

Why It Matters

The metabolic health land grab represents a fundamental shift in pharmaceutical strategy, where mid-cap biotechs with novel obesity and diabetes treatments have become strategic assets worth premium valuations, potentially reshaping the competitive landscape of the entire industry.

Sourcemarkets.chroniclejournal.com

Get stories like this delivered daily

AI-curated news, personalized to your interests. Zero noise.

Start 7-Day Free Trial →

More in Global News